Itoco (Dorzolamide)

Dorzolamide blocks carbonic anhydrase in the eye’s ciliary body, reducing the production of aqueous humor. This decrease in fluid lowers intra‑ocular pressure, a key factor in managing glaucoma and ocular hypertension.

The dosing regimen for Itoco is determined by the prescribing clinician based on the patient’s condition, response, and tolerance. The prescriber will specify the number of drops and frequency appropriate for each individual.

Safety data for dorzolamide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To request Itoco, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Itoco (dorzolamide) belongs to the carbonic anhydrase inhibitor class, which lowers eye pressure by reducing aqueous humor production. Other classes, such as beta‑blockers or prostaglandin analogues, act via different mechanisms. Choice of therapy depends on efficacy, tolerability, patient comorbidities and physician preference.

Itoco should be stored at room temperature, away from direct sunlight and moisture. Keep the bottle tightly closed in its original packaging until use to maintain stability and potency.

Itoco is applied as an eye drop. The patient should wash hands, tilt the head back, pull down the lower eyelid to create a pocket, and place the prescribed number of drops into the eye. Close the eye gently and avoid blinking excessively for a few seconds.

Serious risks include severe allergic reactions, Stevens‑Johnson syndrome, corneal edema, and sudden loss of vision. Patients should seek immediate medical attention if they experience swelling, rash, vision changes, or persistent eye irritation.

Itoco is contraindicated in patients with known hypersensitivity to dorzolamide, sulfonamides, or any component of the formulation. It should also be used with caution in individuals with severe renal impairment or those taking systemic carbonic anhydrase inhibitors.